-
Mashup Score: 227Glucosylceramide accumulation in microglia triggers STING-dependent neuroinflammation and neurodegeneration in mice - 12 day(s) ago
Blocking lipid-induced STING signaling in microglia may slow Gaucher disease–associated neuronal loss.
Source: www.science.orgCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 228Glucosylceramide accumulation in microglia triggers STING-dependent neuroinflammation and neurodegeneration in mice - 14 day(s) ago
Blocking lipid-induced STING signaling in microglia may slow Gaucher disease–associated neuronal loss.
Source: www.science.orgCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 228Glucosylceramide accumulation in microglia triggers STING-dependent neuroinflammation and neurodegeneration in mice - 23 day(s) ago
Blocking lipid-induced STING signaling in microglia may slow Gaucher disease–associated neuronal loss.
Source: www.science.orgCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 231Glucosylceramide accumulation in microglia triggers STING-dependent neuroinflammation and neurodegeneration in mice - 25 day(s) ago
Blocking lipid-induced STING signaling in microglia may slow Gaucher disease–associated neuronal loss.
Source: www.science.orgCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 6Understand the Differences in Carbidopa/Levodopa Formulations for Parkinson Disease - 3 month(s) ago
Understanding differences in the various levodopa formulations and assisting with medication therapy management is a crucial role for pharmacists.
Source: www.pharmacytimes.comCategories: General Medicine News, General Journals & SocietTweet
-
Mashup Score: 15Robotic Garment Improves Stride in Patient With Parkinson's Disease - 3 month(s) ago
A new robotic garment may stop freezing episodes, one of the most disabling features of Parkinson’s disease.
Source: www.medscape.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 5AbbVie Launches PRODUODOPA® (foslevodopa/foscarbidopa) for People Living with Advanced Parkinson's Disease in the European Union - 4 month(s) ago
– PRODUODOPA® (foslevodopa/foscarbidopa) is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of advanced Parkinson’s disease – PRODUODOPA demonstrated…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 175Proximity proteomic analysis of the NRF family reveals the Parkinson’s disease protein ZNF746/PARIS as a co-complexed repressor of NRF2 - 4 month(s) ago
Suppression of NRF2 activity by ZNF746 drives oxidative stress and apoptosis in a neuronal model.
Source: www.science.orgCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 170Proximity proteomic analysis of the NRF family reveals the Parkinson’s disease protein ZNF746/PARIS as a co-complexed repressor of NRF2 - 4 month(s) ago
Suppression of NRF2 activity by ZNF746 drives oxidative stress and apoptosis in a neuronal model.
Source: www.science.orgCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 59
Dysregulated crosstalk between central and peripheral innate and adaptive immune cells triggers and promotes Parkinson’s disease.
Source: www.science.orgCategories: General Medicine News, Future of MedicineTweet
Scientists have deciphered how deficiency of the enzyme GCase—a strong risk factor for #ParkinsonsDisease—provokes neuron-damaging inflammation in the brain, and show that targeting the STING immune pathway can counteract these effects. @SciSignal https://t.co/fcA7obnonL https://t.co/R9rqniluOE